Advancing Treatment for NRG1 Fusion+ Lung and Pancreatic Cancers - Episode 15

Harnessing the Ability to Target NRG1 Fusions in NSCLC, Pancreatic Cancer

Mary B. Beasley, MD, discusses the prevalence of NRG1 fusions in non–small cell lung cancer and pancreatic cancer.

EP. 1: Prevalence of NRG1 Fusions in Lung Cancer
EP. 2: Differences Between DNA and RNA Testing for NRG1
EP. 3: Standard Treatments for NRG1 Fusion+ NSCLC
EP. 4: Ongoing Research Efforts Targeting NRG1 in Lung Cancer
EP. 5: Efficacy With NRG1-Directed Agents in NSCLC
EP. 6: Prognosis, Rarity of NRG1+ Pancreatic Cancer
EP. 7: Choosing RNA Over DNA Testing for NRG1 Fusions in Pancreatic Cancer
EP. 8: Standard Treatment Regimens for NRG1+ Pancreatic Cancer
EP. 9: Poised Potential With Zenocutuzumab in NRG1+ Pancreatic Cancer
EP. 10: Current Approaches and Treatment Challenges in NRG1+ NSCLC and Pancreatic Cancer
EP. 11: DNA vs RNA Sequencing in NSCLC and Pancreatic Cancer
EP. 12: A Physician Assistant's Perspective: Treatment Planning in NRG1+ NSCLC and Pancreatic Cancer
EP. 13: The Potential Role for Zenocutuzumab in NRG1+ NSCLC and Pancreatic Cancer
EP. 14: Using a Multidisciplinary Treatment Approach in NRG1+ NSCLC and Pancreatic Cancer
Now Viewing
EP. 15: Harnessing the Ability to Target NRG1 Fusions in NSCLC, Pancreatic Cancer
EP. 16: The Role of RNA in Detecting NRG1 and Other Fusions in Solid Tumors
EP. 17: The Pathologist’s Role in Molecular Testing in NSCLC, Pancreatic Cancer
EP. 18: Using a Multidisciplinary Approach in NRG1+ NSCLC, Pancreatic Cancer
EP. 19: Overcoming Challenges With Molecular Testing in NSCLC, Other Solid Tumors

Related Content:

Advancing Treatment for NRG1 Fusion+ Lung and Pancreatic CancersThe Tisch Cancer Institute at Mount Sinai Lung CancerPrecision Medicine in Oncology®Pancreatic Cancer
Overcoming Challenges With Molecular Testing in NSCLC, Other Solid Tumors
Using a Multidisciplinary Approach in NRG1+ NSCLC, Pancreatic Cancer
The Pathologist’s Role in Molecular Testing in NSCLC, Pancreatic Cancer